CVR number 27239188
Industry 869600

KIROPRAKTISK KLINIK, NYKØBING F. ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.6% 3.0% 3.7% 3.1% 3.2%  
Credit score (0-100)  53 56 52 55 55  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  5,030 5,251 6,427 6,049 6,754  
EBITDA  946 1,324 1,324 1,328 1,331  
EBIT  718 965 1,056 1,075 1,162  
Pre-tax profit (PTP)  734.3 984.4 1,121.2 1,173.4 1,304.1  
Net earnings  581.8 765.3 874.2 914.7 1,017.0  
Pre-tax profit without non-rec. items  734 984 1,121 1,173 1,304  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  1,337 1,017 796 666 696  
Shareholders equity total  1,589 2,355 3,229 4,144 5,161  
Interest-bearing liabilities  348 86.5 0.0 0.0 0.0  
Balance sheet total (assets)  2,723 3,015 3,720 4,778 5,743  
Net Debt  32.4 -414 -420 -771 -746  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  5,030 5,251 6,427 6,049 6,754  
Gross profit growth  -7.2% 4.4% 22.4% -5.9% 11.7%  
Employees  7 7 7 7 8  
Employee growth %  0.0% 0.0% 0.0% 0.0% 14.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,723 3,015 3,720 4,778 5,743  
Balance sheet change%  49.8% 10.7% 23.4% 28.4% 20.2%  
Added value  946.2 1,324.0 1,324.1 1,344.0 1,331.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  177 -680 -489 -383 -138  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  14.3% 18.4% 16.4% 17.8% 17.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  32.8% 34.7% 33.6% 27.7% 24.9%  
ROI %  46.8% 44.9% 39.6% 31.8% 28.1%  
ROE %  44.8% 38.8% 31.3% 24.8% 21.9%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  58.4% 78.1% 86.8% 86.7% 89.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  3.4% -31.3% -31.7% -58.0% -56.1%  
Gearing %  21.9% 3.7% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  4.1% 5.1% 21.5% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.4 3.6 6.1 6.5 8.9  
Current Ratio  1.4 3.6 6.1 6.5 8.9  
Cash and cash equivalent  316.1 500.7 419.8 770.5 746.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  404.8 1,433.4 2,436.4 3,472.3 4,467.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  135 189 189 192 166  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  135 189 189 190 166  
EBIT / employee  103 138 151 154 145  
Net earnings / employee  83 109 125 131 127